Sudheer Nifa, James Jeslin V
Critical Care Medicine, Star Care Multispeciality Hospital, Kozhikode, IND.
Cureus. 2024 Dec 10;16(12):e75436. doi: 10.7759/cureus.75436. eCollection 2024 Dec.
Fluid management is a crucial critical care component, influencing outcomes such as organ function, renal integrity, and survival in critically ill patients. Recent evidence suggests that balanced crystalloids may offer advantages over isotonic saline, particularly in reducing the risk of acute kidney injury (AKI) and other complications. This study aimed to evaluate the impact of balanced crystalloids versus isotonic saline on clinical outcomes in the intensive care unit (ICU), focusing on AKI, renal replacement therapy (RRT), and mortality. The study also assessed the role of fluid restriction in specific patient populations, including those with acute respiratory distress syndrome (ARDS), sepsis, and heart failure.
A retrospective cohort study included 600 adult patients admitted to the ICU who received fluid therapy between January 2023 and January 2024. Patients were categorized into two groups based on the type of fluid received: 300 patients received balanced crystalloids and 300 received isotonic saline. Outcomes of interest included the incidence of AKI, the need for RRT, overall ICU mortality, oxygenation status (PaO/FiO ratio), duration of mechanical ventilation, cumulative fluid balance, and length of ICU stay. Statistical analyses included multivariate logistic regression to adjust for potential confounders.
The incidence of AKI was significantly lower in the balanced crystalloids group (12% vs. 22%, p = 0.01), with an adjusted odds ratio (OR) of 0.50 (95% CI 0.32-0.78, p = 0.002). The need for RRT was also reduced (8% vs. 15%, p = 0.03), with an adjusted OR of 0.55 (95% CI 0.30-0.95, p = 0.03). Although ICU mortality was lower in the balanced crystalloids group (18% vs. 24%), this difference did not reach statistical significance (p = 0.08). Subgroup analysis showed that in ARDS patients, fluid restriction combined with balanced crystalloids improved oxygenation (PaO/FiO ratio of 220 vs. 180, p = 0.02) and reduced the duration of mechanical ventilation (six vs. nine days, p = 0.01). Similar benefits were observed in sepsis and heart failure patients.
Balanced crystalloids are associated with a significant reduction in AKI incidence and RRT requirement compared to isotonic saline. Fluid restriction, particularly when combined with balanced crystalloids, improves clinical outcomes in patients with ARDS, sepsis, and heart failure. These findings support the preferential use of balanced crystalloids in critically ill patients and highlight the importance of individualized fluid management strategies in the ICU. Further research is needed to confirm these benefits and optimize fluid therapy protocols in diverse ICU populations.
液体管理是重症监护的关键组成部分,影响重症患者的器官功能、肾脏完整性和生存率等结局。最近的证据表明,平衡晶体液可能比等渗盐水具有优势,特别是在降低急性肾损伤(AKI)和其他并发症的风险方面。本研究旨在评估平衡晶体液与等渗盐水对重症监护病房(ICU)临床结局的影响,重点关注AKI、肾脏替代治疗(RRT)和死亡率。该研究还评估了液体限制在特定患者群体中的作用,包括急性呼吸窘迫综合征(ARDS)、脓毒症和心力衰竭患者。
一项回顾性队列研究纳入了2023年1月至2024年1月期间入住ICU并接受液体治疗的600例成年患者。根据所接受液体的类型将患者分为两组:300例患者接受平衡晶体液,300例接受等渗盐水。感兴趣的结局包括AKI的发生率、RRT的需求、ICU总体死亡率、氧合状态(PaO/FiO2比值)、机械通气时间、累积液体平衡和ICU住院时间。统计分析包括多变量逻辑回归以调整潜在的混杂因素。
平衡晶体液组的AKI发生率显著较低(12%对22%,p = 0.01),调整后的优势比(OR)为0.50(95%CI 0.32 - 0.78,p = 0.002)。RRT的需求也有所降低(8%对15%,p = 0.03),调整后的OR为0.55(95%CI 0.30 - 0.95,p = 0.03)。尽管平衡晶体液组的ICU死亡率较低(18%对24%),但这种差异未达到统计学意义(p = 0.08)。亚组分析显示,在ARDS患者中,液体限制联合平衡晶体液可改善氧合(PaO/FiO2比值为220对180,p = 0.02)并缩短机械通气时间(6天对9天,p = 0.01)。在脓毒症和心力衰竭患者中也观察到了类似的益处。
与等渗盐水相比,平衡晶体液与AKI发生率和RRT需求的显著降低相关。液体限制,特别是与平衡晶体液联合使用时,可改善ARDS、脓毒症和心力衰竭患者的临床结局。这些发现支持在重症患者中优先使用平衡晶体液,并强调了ICU中个体化液体管理策略的重要性。需要进一步研究来证实这些益处并优化不同ICU人群的液体治疗方案。